COLUMBIA, Md.--(BUSINESS WIRE)--CELSION CORPORATION (AMEX: CLN) today reported that it had finished its internal review of animal and stability data on its proprietary formulation of docetaxel entrapped in its temperature sensitive liposome. Unlike all other preparations of this compound which require solvents to be used to reconstitute the drug, Celsion has early data demonstrating that its lyophilized formulation can be reconstituted with sterile water which is then ready for use. As a result of this positive program review, future formulation optimization, manufacturing process development and preclinical testing will be moved into a formal development program beginning 2008.
